New combo therapy targets Hard-to-Treat recurrent cancers
NCT ID NCT02208375
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and understand side effects. About 159 participants will be enrolled, and researchers will also look at whether the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Olaparib combined with vistusertib or capivasertib
- What this could lead to
- If successful, this could point toward a new drug combination to help control recurrent cancers that have few options.
- What could go wrong
- This is a very early (Phase 1) trial focused on safety and dosing, not on proving effectiveness. The combination may cause significant side effects and may not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA1 MUTATION CARRIER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a vaccine train the immune system to hunt down hidden breast cancer cells?
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- Immune-Boosting drug combo takes on Hard-to-Treat ovarian cancer
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
- Gene test could guide breast cancer treatment to boost survival